Clinical manifestations and treatment outcomes of pyoderma gangrenosum following rituximab exposure: A systematic review
- PMID: 34942295
- DOI: 10.1016/j.jaad.2021.12.028
Clinical manifestations and treatment outcomes of pyoderma gangrenosum following rituximab exposure: A systematic review
Conflict of interest statement
Conflicts of interest Dr Piguet has received honoraria or fees for consulting and/or speaking for AbbVie, Almirall, Celgene, Janssen, Novartis, and Pfizer and has received departmental support for Cardiff University from AbbVie, Almirall, Alliance, Beiersdorf UK Ltd, Biotest, Celgene, Dermal, Eli Lilly, Galderma, Genus Pharma, Globe Micro, Janssen-Celag, La Roche-Posay, L’Oreal, LEO Pharma, Meda, MSD, Novartis, Pfizer, Sinclair Pharma, Spirit, Stiefel, Samumed, Thornton Ross, TyPham, and UCB and for University of Toronto from Sanofi. Drs Croitoru, Sibbald, Alavi, and Zipursky and authors Nathanielsz, Seigel, and Elsawi do not have any conflicts of interest to disclose.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
